BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Fenofibrate
,
rs7903146
,
TGFB1
,
T cell receptor signaling pathway
,
HIV infection
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
urologic diseases
Summary
General Info
Curated Studies
Most Correlated Studies
OMIM - Urologic disease
Pulmonary metastases and primary tumors of clear-cell RCC with different disease-free survivals
Renal cell carcinoma ischemia induced expression profiles
High-grade prostate cancer cells and normal prostate epithelial cells
Prostate cancer LNCaP orthotopic xenografts of castrated or uncastrated BALB/c nude mice
Explore Curated Studies Results
Literature
Most Relevant Literature
Urologic disease in a resource-poor country.
Pharmacology for common urologic diseases: 2011 review for the primary care physician.
Initial experience with LESS and hybrid LESS in patients with benign urologic disease.
In utero intervention for urologic diseases.
The use of plant uroseptic Uroprofit in urological practice].
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Disea…
Pain Management in Outpatient Urologic Procedures
Urological Complications and Management After Gynecological Operations
Urologic Lymphadenectomy in AMIGO
Duke Urology Database and Specimen Bank
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ